Mouse Genetics Facility

小鼠遗传学设施

基本信息

批准号：
7945024
负责人：
JOSEPH KISSIL
金额：
$ 16.67万
依托单位：
WISTAR INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-15 至 2014-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7945024
关键词：
Animal Rights Animals Arts Back Basic Cancer Research Biological Models Breeding Cancer Center Cancer Model Cancer Research Project Cell Lineage Cell Maintenance Cells Chimera organism Chromatin Collaborations Consultations Cryopreservation Culture Media DNA Derivation procedure Disease Disease model Drug resistance ES Cell Line Electroporation Embryo Embryo Transfer Engineering Equipment Female Freezing Funding Ganciclovir Gene Targeting Gene Transfer Techniques Generations Genetic Genotype Goals Heterozygote Homozygote Human Human Characteristics Human Resources Hybrids In Vitro Inbred C57BL Mice Inbred Mouse Injection of therapeutic agent Institutes Knock-in Mouse Knock-out Laboratories Laboratory Animals Leadership Mammalian Oviducts Microinjections Modification Molecular Genetics Mouse Strains Mus Mutation Oncogenes Operative Surgical Procedures Partner in relationship Pharmaceutical Preparations Procedures Process Production Property Protocols documentation Puromycin Recombinants Reproduction Research Research Personnel Resources Risk Screening procedure Services Source Specialist Staging Stem cells Structure Superovulation System Tail Testing Time Tissues Training Transgenes Transgenic Founder Animals Transgenic Mice Transgenic Organisms Translating Transportation United States National Institutes of Health Uterus Wild Type Mouse animal facility antibiotic G 418 blastocyst design embryonic stem cell experience gene function human disease human embryonic stem cell hygromycin A in vivo instrument lentiviral-mediated male member mouse model mutant pathogen programs reconstitution reproductive research study response stem stem cell technology telomere transmission process tumor vector zygote

项目摘要

The Mouse Genetics Facility was established in 1999 in response to the increasing need of Cancer Center investigators for analysis of gene function in mouse models, and has received Cancer Center support since 2002. Since the last renewal, the Facility has changed leadership, with Dr. Anthony Capobianco now the scientific director of the Facility and Dr. Ping Jiang the facility director. In this funding period, the Institute has invested $167,450 for new and upgraded equipment and renovated laboratory and animal facility space. The Facility provides highly efficient production of both transgenic and knock-out/knock-in (KO/KI) mice, plus it provides a unique resource and expertise in embryonic stem (ES) cell cultivation and engineering, which benefits Cancer Center investigators generating both in vivo and in vitro murine models of cancer. Current services are aligned with the research objectives of the Cancer Center programs and include: (1) production of transgenic mice by pronuclear microinjection of DNA transgene constructs; (2) generation of genetargeted 129 and C57BL mouse ES cell clones; (3) production of chimeric mice derived from microinjection of gene-targeted ES cells into blastocysts; (4) rederivation of mouse lines by embryo transfer; and (5) ES cell cultivation and engineering. Since 2006, the Facility has produced 15 lines of transgenic mice, successfully generated 11 lines of KO/KI mouse ES cell clones, and produced 8 lines of chimeric KO/KI mice. In addition, the Facility successfully rederived a line of an engineered mouse strain and will offer a mouse embryo cryopreservation service in 2008. The Facility is actively collaborating with Cancer Center investigators to utilize its mouse ES cell technology, with the aim of using human ES cells as a vehicle to derive mutant or disease specific cell lineages as a new human disease model system. Goals for the Facility over the next funding period include developing lentiviral mediated transgenesis for some strains of mice that are difficult to produce with DNA microinjection, developing use of tetraploid complementation as an efficient approach to produce chimeras from injections of ES cells of C57BL origin into blastocysts, and establishing human ES cell cultivation and engineering as a routine service.

小鼠遗传学设施是在1999年建立的，以响应癌症中心的需求增加研究人员用于分析小鼠模型中的基因功能，并且自从获得癌症中心的支持以来 2002年。自上次续签以来，该设施改变了领导才能，安东尼·卡普比亚科（Anthony Capobianco）博士现在该设施的科学总监和江博士设施主管。在这个资金期间，研究所已经为新的和升级的设备以及翻新的实验室和动物设施空间投资了167,450美元。该设施提供了转基因和敲除/敲门（KO/Ki）小鼠的高效产生，加上它提供了胚胎茎（ES）细胞种植和工程的独特资源和专业知识，受益于癌症中心的研究人员，生成体内和体外鼠模型的癌症模型。当前的服务与癌症中心计划的研究目标保持一致，包括：（1）生产通过对DNA转基因构建体的前核显微注射的转基因小鼠；（2）产生的基因目标 129和C57BL小鼠ES细胞克隆；（3）产生源自显微注射的嵌合小鼠靶向基因的ES细胞成胚泡；（4）通过胚胎转移重新培养小鼠线；（5）ES细胞耕种和工程。自2006年以来，该设施已经生产了15行转基因小鼠，成功生成了11行KO/Ki小鼠ES细胞克隆，并产生了8行嵌合KO/Ki小鼠。此外，该设施成功重新修复了工程鼠标应变的线，并将提供鼠标胚胎冷冻保存服务于2008年。该设施正在与癌症中心的调查人员积极合作利用其小鼠ES细胞技术，目的是使用人ES细胞作为推导突变体或特定于疾病的细胞谱系作为一种新的人类疾病模型系统。下一个设施的目标资金期包括开发一些困难的小鼠菌株的慢病毒介导的转基因用DNA显微注射产生，将四倍体互补用作有效方法发展从C57BL起源的ES细胞注射中产生嵌合体，并建立人ES 细胞种植和工程作为常规服务。